Literature DB >> 15932016

Toll-like receptors: linking innate and adaptive immunity.

Chandrashekhar Pasare1, Ruslan Medzhitov.   

Abstract

Work in recent years has shown an essential role for Toll-like receptors (TLRs) in the activation of innate and adaptive immunity in vertebrate animals. These germ-line encoded receptors, expressed on a diverse variety of cells and tissues, recognize conserved molecular products derived from various classes of pathogens, including Gram-positive and -negative bacteria, DNA and RNA viruses, fungi and protozoa. Ligand recognition induces a conserved host defense program, which includes production of inflammatory cytokines, upregulation of costimulatory molecules, and induction of antimicrobial defenses. Importantly, activation of dendritic cells by TLR ligands is necessary for their maturation and consequent ability to initiate adaptive immune responses. How responses are tailored by individual TLRs to contain specific classes of pathogens is not yet clear.

Mesh:

Substances:

Year:  2005        PMID: 15932016     DOI: 10.1007/0-387-24180-9_2

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  165 in total

1.  Dysregulation of immune homeostasis in autoimmune diseases.

Authors:  Vijay K Kuchroo; Pamela S Ohashi; R Balfour Sartor; Carola G Vinuesa
Journal:  Nat Med       Date:  2012-01-06       Impact factor: 53.440

Review 2.  Toll-like receptors and B-cell receptors synergize to induce immunoglobulin class-switch DNA recombination: relevance to microbial antibody responses.

Authors:  Egest J Pone; Hong Zan; Jingsong Zhang; Ahmed Al-Qahtani; Zhenming Xu; Paolo Casali
Journal:  Crit Rev Immunol       Date:  2010       Impact factor: 2.214

Review 3.  Genome-Wide Approaches to Defining Macrophage Identity and Function.

Authors:  Gregory J Fonseca; Jason S Seidman; Christopher K Glass
Journal:  Microbiol Spectr       Date:  2016-10

Review 4.  The role of Toll-like receptors in CNS response to microbial challenge.

Authors:  Gregory W Konat; Tammy Kielian; Ian Marriott
Journal:  J Neurochem       Date:  2006-08-08       Impact factor: 5.372

Review 5.  Infectious disease, the innate immune response, and fibrosis.

Authors:  Alessia Meneghin; Cory M Hogaboam
Journal:  J Clin Invest       Date:  2007-03       Impact factor: 14.808

6.  Loss of transgene following ex vivo gene transfer is associated with a dominant Th2 response: implications for cutaneous gene therapy.

Authors:  Zhenmei Lu; Soosan Ghazizadeh
Journal:  Mol Ther       Date:  2007-03-13       Impact factor: 11.454

7.  Nonclassical pathway of Pseudomonas aeruginosa DNA-induced interleukin-8 secretion in cystic fibrosis airway epithelial cells.

Authors:  Mónica A Delgado; Jens F Poschet; Vojo Deretic
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

8.  Escherichia coli strain Nissle 1917 ameliorates experimental colitis via toll-like receptor 2- and toll-like receptor 4-dependent pathways.

Authors:  A Grabig; D Paclik; C Guzy; A Dankof; D C Baumgart; J Erckenbrecht; B Raupach; U Sonnenborn; J Eckert; R R Schumann; B Wiedenmann; A U Dignass; A Sturm
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

9.  Glioprotective Effects of Lingonberry Extract Against Altered Cellular Viability, Acetylcholinesterase Activity, and Oxidative Stress in Lipopolysaccharide-Treated Astrocytes.

Authors:  Simone Muniz Pacheco; Juliana Hofstätter Azambuja; Taíse Rosa de Carvalho; Mayara Sandrielly Pereira Soares; Pathise Souto Oliveira; Elita Ferreira da Silveira; Francieli Moro Stefanello; Elizandra Braganhol; Jessié Martins Gutierres; Roselia Maria Spanevello
Journal:  Cell Mol Neurobiol       Date:  2018-03-19       Impact factor: 5.046

10.  The myeloid differentiation factor 88 (MyD88) is required for CD4+ T cell effector function in a murine model of inflammatory bowel disease.

Authors:  Masayuki Fukata; Keith Breglio; Anli Chen; Arunan S Vamadevan; Tyralee Goo; David Hsu; Daisy Conduah; Ruliang Xu; Maria T Abreu
Journal:  J Immunol       Date:  2008-02-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.